Oncology (all articles)
M-A | Prevalence of polypharmacy and potentially inappropriate medication use in older lung cancer patients
9 Feb, 2023 | 13:24h | UTC
M-A | Risk of endometrial cancer in postmenopausal women in relation to ultrasonographic endometrial thickness
8 Feb, 2023 | 12:21h | UTCRisk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
Commentary on Twitter
AJOG Systematic Review: Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis https://t.co/uxPx8Jr160 pic.twitter.com/LugkrnKmjr
— AJOG (@AJOG_thegray) December 30, 2022
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma
7 Feb, 2023 | 14:09h | UTC
M-A | Effectiveness of therapeutic exercise models on cancer-related fatigue
7 Feb, 2023 | 13:46h | UTCRelated:
ASCO Guideline: Exercise, diet, and weight management during cancer treatment.
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
Five reasons physical activity is important for cancer patients – The Conversation
Updating international consensus on best practice in care of the dying: a Delphi study
6 Feb, 2023 | 13:41h | UTC
Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
6 Feb, 2023 | 13:20h | UTCInvited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open
Commentary on Twitter
Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
M-A | Risk of second primary cancer among breast cancer patients
6 Feb, 2023 | 13:10h | UTC
SR | Partial breast irradiation for breast cancer
3 Feb, 2023 | 14:06h | UTCPartial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality
RCT | First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma
3 Feb, 2023 | 14:02h | UTC
M-A | Treatment- and immune-related AEs of checkpoint inhibitors in esophageal or gastroesophageal junction cancer
3 Feb, 2023 | 13:55h | UTC
M-A | Major complications and mortality after resection of intrahepatic cholangiocarcinoma
3 Feb, 2023 | 13:43h | UTC
M-A | Risk of non-hormonal cancer after bariatric surgery
2 Feb, 2023 | 14:37h | UTCRisk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies – British Journal of Surgery (link to abstract – $ for full-text)
Commentary: Bariatric Surgery May Reduce the Risk of Some Common Cancers – National Cancer Institute
M-A | Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer
2 Feb, 2023 | 14:36h | UTC
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
SR | Immediate breast reconstruction uptake in older women with primary breast cancer
1 Feb, 2023 | 13:04h | UTC
M-A | Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma
31 Jan, 2023 | 13:42h | UTC
SR | There is insufficient evidence to recommend corticosteroids for the management of cancer‐related fatigue
30 Jan, 2023 | 00:47h | UTC
RCT | Adjuvant temozolomide with or without interferon alfa in patients with newly diagnosed high-grade gliomas
30 Jan, 2023 | 00:27h | UTCCommentary: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor
Commentary on Twitter
This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G
— JAMA Network Open (@JAMANetworkOpen) January 27, 2023
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27 Jan, 2023 | 12:16h | UTC
M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions
27 Jan, 2023 | 12:11h | UTC
Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma
27 Jan, 2023 | 12:01h | UTC
Commentary on Twitter
Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) December 6, 2022
M-A | Proximal gastrectomy with double-tract-reconstruction vs. total gastrectomy in gastric and gastroesophageal junction cancer patients
27 Jan, 2023 | 11:54h | UTC
Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy
26 Jan, 2023 | 12:09h | UTC